PRTC
PureTech Health plc
NASDAQ · Healthcare · Biotechnology · US
$17.38
+2.12%Jun 9, 2026, 06:00 UTC
Seaport Therapeutics reported positive multiple-ascending dose data from a Phase 1 proof-of-concept trial of GlyphAgo in healthy volunteers.
Source: